Inhibitory antibodies to factors VIII or IX represent a serious complication for hemophilia patients.
ABSTRACT
Inhibitory antibodies to factors VIII or IX represent a serious complication for hemophilia patients.
Treatment involves products that bypass the intrinsic pathway and promote thrombin generation. Direct infusion of factor Xa should also restore hemostasis; however it has a short half-life in plasma and could activate systemic coagulation in an uncontrolled fashion. Here we show that factor Xa mutants with zymogen-like properties (FXa I16L and FXa
V17A
) circumvent these limitations. In the absence of factor Va, the FXa variants are poor enzymes for a range of physiological ligands and are resistant to inactivation by antithrombin III and tissue factor pathway inhibitor. Notably, assembly of FXa I16L and FXa V17A on activated platelets with factor Va to form prothrombinase completely restores biologic activity. In hemophilic plasma, FXa I16L and FXa V17A have prolonged half-lives compared to wild-type factor Xa (~60 min versus ~1 min) and promote robust thrombin generation that bypasses the intrinsic pathway. The variants require factor Va generated in situ for procoagulant function and cofactor inactivation by the protein C pathway regulates their activity. The efficacy, extended half-life and mechanism of action suggest that novel zymogen-like forms of factor Xa might prove useful as new therapeutic procoagulants to treat deficiencies upstream of the common pathway.
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INTRODUCTION
The blood coagulation zymogen factor X (FX) occupies a central position in the coagulation cascade. It is the principal physiological substrate for the extrinsic (tissue factor (TF)/FVIIa) and intrinsic (FVIIIa/FIXa) tenase complexes thus linking these two pathways. 1 These enzymes cleave FX at a conserved site (between Arg 15 -Ile 16 ; chymotrypsin numbering 2 ) thereby liberating an activation peptide and a new N-terminus (Ile 16 -Val-Gly-Gly..). The α-amino group from Ile 16 in the heavy chain forms a salt bridge with Asp 194 which drives a conformational change that leads to maturation of the catalytic domain and imparts function. 3, 4 For FX/FXa, the zymogen to protease transition not only drives catalytic site activation but also contributes to the formation of the FVa binding site. 5, 6 Once FXa binds FVa on an anionic membrane surface in the presence of Ca 2+ ions to form prothrombinase the macromolecular enzyme complex rapidly converts prothrombin to thrombin. 1 While free FXa catalyzes this reaction, prothrombinase is considered the physiologically relevant enzyme. In addition to its role in prothrombinase, FXa activates other coagulation factors including FV, FVIII, and FVII and may play a role in activating protease activated receptors (PARs). [7] [8] [9] [10] Regulation of FXa biologic activity is mediated in part through its tight interaction with tissue factor pathway inhibitor (TFPI) with subsequent inhibition of FVIIa/TF and by its rapid and essentially irreversible inhibition by serpins including antithrombin III (ATIII). 11, 12 Hemophilia is characterized by a congenital deficiency of FVIII (hemophilia A; HA) or FIX (hemophilia B; HB) and results in an inadequate production of FXa and ultimately thrombin. 13 The mainstay of hemophilia therapy is intravenous replacement of the missing or dysfunctional FVIII or FIX with either plasma-derived or recombinant protein products. Unfortunately, ~20-30% of patients with FVIII deficiency and ~3-5% of patients with FIX deficiency produce inhibitory antibodies to the infused protein products. 14 This has prompted the development of bypass strategies that use other coagulation factors to restore hemostasis in these patients, including recombinant FVIIa and activated prothrombin complex concentrates (aPCC) which contains a mixture of prothrombin complex zymogens and their
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From activation products. 15, 16 Although effective in most cases, their efficacy can vary and in some circumstances these products can increase the morbidity of the disease. 17, 18 Furthermore, these products are costly and some are derived from plasma with risk of blood borne disease.
In principle wild-type (wt)-FXa should be the ideal candidate to bypass deficiencies in the intrinsic pathway as it is the enzyme product which is lacking in hemophilia. However, there are serious limitations inherent to FXa that make it unviable. For example, it is rapidly inactivated by plasma protease inhibitors, resulting in a short half-life. 19, 20 Additionally, the FXa which escapes inhibition could cause excessive activation of systemic coagulation through the direct activation of procoagulant coagulation factors (e.g. FV and FVIII), further limiting its utility. Previous attempts using FXa either alone or in combination with phospholipids in a hemophilic dog model have borne out these limitations. 21, 22 Recently our laboratory has characterized variants of FXa that could circumvent these associated problems. 6 These FXa derivatives have a mutation at either position 16 or 17 at the Nterminus of the heavy chain (e.g. FXa I16L and FXa
V17A
). Biochemical studies revealed that these mutations destabilize the normal zymogen to protease conversion process. As a consequence, these proteins have "zymogen-like" properties characterized by the free enzyme having low activity resulting from altered active site binding and function. Surprisingly, activity can be rescued with saturating concentrations of FVa, and once assembled into prothrombinase the FXa variants function comparably to wt-FXa. Based on these features, we speculate that zymogen-like forms of FXa should act as long-lived proteases in circulation that are otherwise functionally inert in the absence of FVa but retain the ability to catalyze thrombin formation upon FVa binding on an activated cellular surface. In the current study we explore this possibility using in vitro systems of increasing complexity and examine the potential of zymogen-like FXa variants to serve as procoagulants to bypass deficiencies in the intrinsic pathway.
METHODS
Reagents. The peptidyl substrate methoxycarbonyl-cyclohexylglycyl-glycyl-arginine-ρ-nitroanilide (Spectrozyme FXa, SpecXa) was from American Diagnostica (Greenwich, CT) and H-D-phenylalanylpipecolyl-arginine-ρ-nitroanilide (S-2238) was purchased from Diapharma Group, Inc. (West Chester, OH). Substrate solutions were prepared in water and concentrations were verified using E 342 = 8270 M -1 cm -1 . 23 The inhibitors benzamidine and 4-amidinophenylmethanesulfonyl fluoride hydrochloride (APMSF) were from Sigma (St. Louis, MO) and dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (DAPA) was from Haematologic Technologies (Essex Junction, VT). All tissue culture reagents were from Invitrogen (Carlsbad, CA) except insulin-transferrin-sodium selenite which was from Roche (Indianapolis, IN). Small unilamellar phospholipid vesicles (PCPS) composed of 75% (w/w) hen egg L-α-phosphatidlycholine and 25% (w/w) porcine brain L-α-phosphatidylserine (Avanti Polar Lipids, Alabaster, AL) were prepared and characterized as described. 24 Technothrombin thrombin calibrator and thrombin generation assay (TGA) reagent RB was purchased from Diapharma Group, Inc (West Chester, OH). The fluorogenic substrate Z-Gly-Gly-Arg-AMC was purchased from Bachem Bioscience, Inc. Proteins. Human prothrombin, FX and FV were isolated from plasma as described previously. 25, 26 Thrombin was obtained from Haematologic Technologies and hirudin was from EMD Biosciences (San Diego, CA). The FX activator from Russell's viper venom (RVV X-CP ) was purified as described previously. 27 Human plasma-derived FVa or recombinant FVa (rFVa) was prepared by proteolytic activation of FV or FV-810 by thrombin and purified as described. 28 Recombinant wild-type FX (wt-FX), and two zymogen-like variants (FX  I16L and FX   V17A ) were prepared, purified and characterized as previously described. 5, 6 Recombinant and plasma-derived FX (pd-FX) were activated with RVV X-CP and purified as described. 5 Prothrombin activation on isolated human platelets. Human platelets were isolated from freshly collected whole blood as previously described. 35 Institutional review board approval was given by the Children's Hospital Research Institute for isolating human platelets from blood drawn from subjects.
Prothrombinase-catalyzed prothrombin activation using thrombin-activated platelets was determined as previously described. 35 Platelets ( and initial rates of thrombin generation were determined as previously described using S-2238. were incubated with PCPS (50 µM) and increasing concentrations of wt-FXa or variant FXa (0.5-100 nM). Following 10 min incubation at 25°C, samples (4 µg/lane) were prepared for electrophoresis using 4-12% gradient gels (Invitrogen) under reducing conditions using the MOPS or MES buffer system followed by staining using Coomassie Brilliant Blue R-250.
FXa-specific clotting assays. Factor Xa procoagulant or bypassing activity was measured using a modified aPTT in hemophilic plasma. In a typical assay, 50 µl of HA, HB, or HA plasma with inhibitors was mixed with an equal volume of aPTT reagent followed by a 180 second incubation period at 37°C. A 50 µl mixture of FXa (0.1 nM) with or without FVa (10 nM) in assay buffer was then added to the solution and coagulation was initiated following the addition of 50 µl of 25 mM CaCl 2 . Time to clot formation was measured using a Start4 coagulation instrument (Diagnostica Stago, Inc., Parsippany, NJ).
For half-life determinations, FXa (20 nM, final) was incubated in hemophilic plasma at room temperature
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Residual FXa bypassing activity was assessed as detailed above.
Thrombin generation assays. Thrombin generation in platelet poor plasma was determined according to methods previously described with some modifications. 36 Normal or hemophilic plasma was mixed with a TF-phospholipid reagent ( was added to the microtiter plate followed by the immediate addition of Z-Gly-Gly-Arg-AMC in 15 mM
CaCl 2 (50 µl; 0.5 mM, final). For experiments in which the PC pathway was introduced into the thrombin generation assay, serial dilutions of sTM or APC were prepared in hemophilic plasma just prior to the addition of the TF-phospholipid reagent. Fluorescence was measured over 90 minutes at 37°C in a
Spectramax M2 e (Molecular Devices, Sunnyvale, CA) with excitation and emission wavelengths set at 360 nm and 460 nm, respectively. Raw fluorescence values were compared to a thrombin calibration curve generated using a thrombin calibrator (Technothrombin TGA calibrator) to convert the signal to nM thrombin. Thrombin generation curves (nM thrombin versus time) were analyzed to extract lag time, peak height, and endogenous thrombin potential (ETP). ETP is the area under the thrombin generation curve and represents a measure of the total amount of thrombin generated in plasma.
Data analysis. Data were analyzed according to the referenced equations by nonlinear least squares regression. Reported estimates of error represent ± 2 S.D. The qualities of the fits were assessed by the criteria described. 37 Initial velocity measurements of prothrombin activation by prothrombinase were analyzed by fitting the data to the Henri-Michaelis-Menten equation to yield fitted values for K m and V max . 38 The rate of inhibition of FXa or prothrombinase by ATIII was measured under pseudo-first-order rate conditions and the second-order rate constant was calculated by dividing the pseudo first order rate constant (k obs ) by the concentration of ATIII as previously described. 39 Determination of the overall equilibrium dissociation constant (K i *) for TFPI binding to FXa was determined according to equations previously described. 40 For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
RESULTS
Characterization of FXa variants using physiological ligands. Wild-type FXa is rapidly inactivated in vivo by ATIII and TFPI which neutralize the enzyme largely via active site binding interactions. 19, 20 Kinetic studies using purified proteins showed that the inhibition of FXa I16L by ATIII was substantially altered relative to wt-FXa ( Figure 1A and B, Table 1 ). Analysis of the data for FXa I16L and FXa
V17A
revealed that the second order rate constant for inhibition was reduced by 25-40-fold relative to wt-FXa.
Similarly, the variants were also resistant to TFPI resulting from weak binding of the inhibitor to the mutant proteases (K i * increased by ~20-fold; Figure 1C and 1D; Table 1 ). Together these results indicate that the active site of the zymogen-like variants is not readily accessible to the physiological inhibitors, making them partially resistant and potentially protected from inactivation once introduced into the circulation.
In contrast to these data with the free enzyme, incorporation of FXa I16L or FXa V17A into prothrombinase altered the active site of the proteins such that the level of inhibition by ATIII was now comparable to wt-FXa (Table 1) . However, the data show that the second order rate constants for the inhibition of prothrombinase (with wt or variant FXa) versus free FXa is markedly reduced. These data are in general agreement with prior reports suggesting that prothrombinase is poorly inhibited by ATIII. 41, 42 Consistent with the idea that FXa I16L or FXa V17A have altered active site structure and function in the absence of FVa, the ability of these proteins to activate a range of physiological ligands was also suboptimal. Specifically, we found that the rate of FV cleavage with FXa I16L in the presence of phospholipids was markedly reduced compared to wt-FXa ( Figure 2 Prothrombin activation on thrombin-activated human platelets. Previous initial velocity studies using synthetic anionic phospholipids vesicles (PCPS) and saturating amounts of FVa revealed that the zymogen-like variants and wt-FXa activate prothrombin with similar kinetics. 6 To extend these results to a more physiological surface, we pursued experiments using thrombin activated platelets. Assembly of Table 2 ). In these experiments, it is important to note that coagulation is immediately initiated following the addition of FXa in an attempt to minimize its inactivation by plasma inhibitors. Introduction of FXa I16L or FXa V17A (0.1 nM) to HA plasma shortened the clotting time to ~53 sec and 56 sec, respectively and were ~20% as effective as wt-FXa. Similar results were obtained using HB plasma and plasma with neutralizing inhibitors against FVIII (Table 2) .
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Previous studies indicate that FV activation in hemophilic plasma, depending on reaction conditions, can be delayed. 43 If this is the case, it is possible that in our assay system insufficient amounts of activated FV are being generated during the initiation of coagulation leading to sub-optimal rescue of the zymogen-like FXa variants. To test this hypothesis, FVa (10 nM) was directly introduced into HA plasma along with FXa. As a control, the addition of FVa to HA plasma without FXa had only a minor effect on the clotting time (Table 2) ; however, the activity of the zymogen-like variants was markedly increased when added with FVa. The aPTT clotting times for FXa I16L and FXa V17A were shortened from ~54 sec to ~32 sec, corresponding to ~50% activity relative to wt-FXa (with added FVa) versus ~20% in the absence of added FVa; similar results were obtained with HB plasma and HA inhibitor plasma ( Table   2 ). Thus while the FXa variants have substantial bypassing activity in hemophilic plasma, this can be augmented either by co-administration with exogenous FVa or under conditions that favor enhanced FV activation.
To extend this analysis in another system, we employed a thrombin generation assay. 36 In this system initiation of coagulation with 2 pM TF yields a robust signal with pooled NHP whereas thrombin generation is essentially undetectable using HA plasma (Figure 4 ). ) was sufficient to restore thrombin generation in HA plasma in a dose dependent manner ( Figure 4 and Table 2 ). Under these conditions, 0.1 nM FXa was able to fully restore the ETP to an extent comparable to NHP. Not surprisingly, the lag time and time to peak were shortened relative to NHP following the addition of FXa. Interestingly, both FXa
I16L
, and FXa V17A appeared to be equally or even slightly more effective on a molar basis than wt-FXa. This could be due to the possibility that sufficient amounts of FVa are generated during the thrombin generation assay to fully rescue the FXa variants. Alternatively, it could also be related to the different half-lives of the wild-type and variant FXa in plasma (see below) as there is a time delay (<1 min) prior to the start of the thrombin generation assay.
As expected, similar results were obtained using HB plasma and plasma with inhibitors against FVIII ( Figure 4C ). Like the FXa variants, increasing amounts of rFVIIa shortened the lag time and time to peak (data not shown). These in vitro data provide some measure of how well the FXa zymogen-like variant works, compared to an existing bypass agent, at restoring thrombin generation in hemophilic plasma using a low TF stimulus.
Half-life studies in hemophilic plasma. , or FXa V17A were incubated in HA plasma for various periods of time and residual clotting activity was monitored ( Figure 5 and Table 2 ). Consistent with previous reports, 19, 44 wt-FXa is rapidly inhibited in plasma with a half-life of ~1 min. In contrast, the half-lives of FXa I16L and FXa V17A were markedly prolonged and estimated to be ~1 hr. Similar results were obtained using a chromogenic method and a thrombin generation assay to monitor residual FXa activity in hemophilic plasma with half-lives estimated to be ~90 min for the variants and ~1 min for wt-FXa (data not shown). Taken together, these results suggest that the zymogen-like conformation of FXa I16L and FXa V17A protects the proteins in a plasma environment where there is a high concentration of protease inhibitors.
Regulation of the zymogen-like variants by the PC pathway.
Since the FXa zymogen-like variants display significant resistance to plasma inhibitors, an important question that emerges is how would these proteins be regulated in a physiological setting. In vivo, APC cleaves and inactivates FVIIIa and FVa, thereby attenuating the intrinsic and common pathways, respectively. Since our data show that the zymogen-like FXa variants require FVa to be conformationally rescued, we tested the impact of the PC pathway on regulating thrombin generation following a TF-stimulus using FXa I16L and FXa
V17A
. To
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Presumably, these findings result from the ability of sTM to complex with thrombin generated in situ to promote the activation of PC to APC ultimately leading to the inactivation of FVa. Interestingly, there was minimal influence on the lag time which is likely due to the fact that thrombin must first be generated to complex with sTM and yield APC before there is any measurable impact on the further generation of thrombin. Similar results were obtained with the direct addition of APC. APC (1.0-20 nM) caused a dose-dependent reduction in total thrombin generation, however in contrast to sTM an increase in the lag time was also observed (data not shown). Collectively these data indicate that inactivation of FV/Va by the PC pathway effectively regulates zymogen-like FXa function. In further support of this, thrombin generation could not be rescued with FXa I16L or FXa V17A using FV-deficient plasma, reinforcing the idea that FVa is essential to rescue the procoagulant activity of the zymogen-like variants.
DISCUSSION
Over the past three decades substantial progress has been made in managing hemophilia patients with inhibitory antibodies to FVIII or FIX.
14 Protein-based products that bypass the intrinsic pathway, such as FVIII bypassing agents (e.g. APCCs) and recombinant FVIIa, are effective in treating these patients. 15, 16 These products reconstitute thrombin generation by enhancing cell surface FXa production and ultimately prothrombinase levels. 43, 45 However, their short half-lives, effective dose range, cost and potential for thrombotic complications indicates that other approaches that enhance thrombin generation should be explored. Several groups have initiated this process and include a full range of strategies such as high activity FVIIa variants, 46 FXIIa implants, 47 reversibly acylated FXa, 48 and thrombin-activable FX. 44 Previous work in the 1980s using a canine hemophilia model examined the possibility of using FXa or FXa in combination with anionic phospholipids as a hemostatic agent to treat hemophilia. 22 However, these attempts ultimately proved unsuccessful due to FXa's very short half-life and its potential to induce disseminated intravascular coagulation. Together, these associated problems proved too much to overcome essentially eliminating the possibility of FXa as a bypass product.
Our recent investigation into the zymogen to protease transition for FX/FXa and the identification of novel zymogen-like FXa variants prompted us to re-consider the utility of an alternative "FXa bypass". A key feature in the effectiveness of the FXa zymogen-like variants in promoting thrombin generation in plasma is their ability to be rescued by FVa generated in situ. 6 We have previously shown that these proteins have a modestly reduced affinity for FVa (~10-fold increased K d ) compared to wt-FXa.
Therefore the level of endogenous FVa generated during an assay or in vivo will determine the extent to
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From which the zymogen-like variants are rescued. It was clear that during certain assays, such as the aPTT clotting assay, additional amounts of FVa were needed to fully rescue the zymogen-like variants. This likely reflects the reduced rate of FV activation during this assay and hence the amount of FVa available during the initiation of coagulation in hemophilic plasma. However, this was not the case when using the thrombin generation assay or when assessing the activity of the FXa variants on thrombin activated platelets where no additional FVa was required. The results on thrombin activated platelets using only α-granule released FV/FVa are interesting and suggest that sufficient amounts of FVa would be available at the platelet surface to fully rescue the zymogen-like FXa variants. This is a key point to consider since the variants would be effectively regulated or turned on by platelet-derived FVa at the activated platelet surface, which is considered to be the primary site for the initial burst of thrombin. 45 While the FXa zymogen-like variants are resistant to plasma protease inhibitors, they are regulated indirectly by the PC pathway. Introduction of either sTM or APC to plasma attenuated FXa-induced thrombin generation and neither wild-type nor zymogen-like FXa proteins could rescue clotting or thrombin generation in FV-deficient plasma. While these results were to a certain extent expected, they advance our understanding of how the variants may be regulated in vivo. Thus the generation of thrombin using the FXa zymogen-like variants should be under the same controls as wt-FXa when in prothrombinase (e.g. based on availability of active FVa and negatively charged phospholipids) while strict regulation of the free enzyme is of less importance as the zymogen-like variants are relatively inert in the absence of FVa.
Finally, it is notable that FXa I16L and FXa V17A restored thrombin generation in hemophilic plasma at much lower concentrations than rFVIIa. Clearly, the magnitude of these differences would be expected to be different if higher concentrations of TF were employed or if the phospholipid compositions/concentrations were optimized for FVIIa in this assay. However, from a clinical standpoint it is well established that high levels of exogenous FVIIa are needed for a full thrombin burst and ultimately hemostatic efficacy. This is thought to be due to its mechanism of action which principally involves FVIIa activation of FX on activated platelets in a TF-independent fashion, a reaction that is very
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From inefficient. Additional contributions are also derived from a TF-dependent mechanism and a mechanism involving overcoming FVII binding to TF. 15, [50] [51] [52] Like FVIIa, the zymogen-like FXa variants would also be expected to work at the platelet surface; however, the FXa variants would rely on platelet-derived FVa or FVa available from plasma to activate prothrombin. Thus these differences in mechanism of action may translate into potentially significant dose advantages for the FXa variants compared to rFVIIa while maintaining high hemostatic efficacy. Detailed studies in hemophilic animal models using species specific proteins comparing these bypass agents will assist in deciphering these differences.
In summary our data show that zymogen-like FXa variants restore thrombin generation and clotting in human hemophilic plasma in a FVa-dependent fashion and importantly have an extended half-life relative to wt-FXa. Prior to the initiation of coagulation where FVa is essentially absent, the zymogenlike variants will be functionally inert and would not be expected to activate systemic coagulation in an uncontrolled fashion. However once FVa is generated in situ or released from platelet α-granules following the initiation of the hemostatic process, the FXa variant will find its way unabated to the activated platelet surface, assemble in prothrombinase and generate a burst of thrombin at the site of injury. Limits on the availability of FVa, or its subsequent inactivation by the PC pathway effectively regulates zymogen-like FXa function. The efficacy, prolonged half-life, and regulation by cofactor expression suggest that these FXa variants might prove useful and safer as therapeutic procoagulant bypass agents to treat deficiencies upstream of the common pathway. Future in vivo studies will help us further delineate the clinical utility of zymogen-like FXa for this purpose. 
FIGURE 2
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